VYNE Therapeutics (NASDAQ:VYNE) Posts Earnings Results, Beats Expectations By $0.10 EPS

VYNE Therapeutics (NASDAQ:VYNE) announced its quarterly earnings data on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.10, FiscalAI reports. VYNE Therapeutics had a negative return on equity of 74.86% and a negative net margin of 4,646.14%.The company had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.20 million.

VYNE Therapeutics Price Performance

NASDAQ VYNE traded down $0.00 on Friday, reaching $0.67. The stock had a trading volume of 106,393 shares, compared to its average volume of 292,626. The firm has a fifty day moving average of $0.62 and a two-hundred day moving average of $0.54. VYNE Therapeutics has a 1-year low of $0.28 and a 1-year high of $1.96. The company has a market cap of $22.32 million, a P/E ratio of -0.86 and a beta of 2.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in VYNE Therapeutics in the 4th quarter valued at $46,000. Geode Capital Management LLC grew its holdings in VYNE Therapeutics by 64.2% in the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after buying an additional 88,030 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in VYNE Therapeutics in the 2nd quarter valued at $176,000. Jane Street Group LLC acquired a new position in VYNE Therapeutics in the 2nd quarter valued at $206,000. Finally, Two Sigma Investments LP acquired a new position in VYNE Therapeutics in the 3rd quarter valued at $74,000. 83.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on VYNE shares. Wall Street Zen raised VYNE Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.